The British pharmaceutical company GSK and US partner Vir Biotechnology announced on Tuesday that the United States had agreed to buy an additional 600,000 doses of coronavirus sotrovimab antibody therapy for an undisclosed price.
The agreement is part of the US government’s efforts to strengthen its “arsenal” of treatments for the Omicron variant of the coronavirus.
The two pharmaceutical companies have announced that additional doses of antibody therapy will be delivered to the US government for distribution in the first quarter of 2022.
It is recalled that the US had signed a $ 1 billion deal with the two companies in November to supply an unspecified number of doses of GSK-Vir monoclonal antibody therapy.
Sotrovimab, which is given by infusion, belongs to the class of monoclonal antibodies. These are compounds that are developed in the laboratory and mimic the body’s natural defenses. Tests have shown that the treatment works in the treatment of the rapidly transmitted Omicron variant.
Including the latter agreement, the two companies have so far entered into an agreement to supply approximately 1.7 million doses of antibody therapy worldwide.
.
Source From: Capital
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.